Exclusive Summary

• Strategic Regulatory & Financial Incentives: FDA Orphan Drug Designation (ODD) grants a waiver of PDUFA fees (valued at ~$3M+) and potential 7-year market exclusivity, significantly de-risking the investment for licensing partners.
• High-Margin Niche Market: Targeting rare diseases ensures a 'Limited Competition' landscape, allowing partners to maintain premium pricing and superior profit margins compared to mass-market generics.
• Cost-Efficiency & Supply Chain Strength: Leveraging Chinese manufacturing efficiency allows for a competitive pricing strategy against expensive originators, creating a compelling value proposition for payers and partners.

Asset Materials

Contact Us for Full Materials